A Two-Step Toward Personalized Therapies for Prostate Cancer

See allHide authors and affiliations

Science Translational Medicine  02 Mar 2011:
Vol. 3, Issue 72, pp. 72ps7
DOI: 10.1126/scitranslmed.3002169

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Identifying the dominant genetic alterations that drive tumorigenesis is essential for developing targeted cancer therapies. Recent work has demonstrated that prostate tumors can be stratified by dominant genetic alterations, such as chromosomal rearrangements involving ETS (Erythroblastosis virus E26 transformation-specific) family transcription factors or overexpression of SPINK1, a gene that encodes a secreted serine protease inhibitor. In this issue of Science Translational Medicine, Ateeq et al. provide evidence to support a rationale for targeting the SPINK1 protein in the SPINK1+/ETS subset of prostate tumors and also describe a potential interaction of SPINK1 with epidermal growth factor receptor that could be an additional target for therapeutic intervention.


  • Citation: A. S. Goldstein, Y. Zong, O. N. Witte, A Two-Step Toward Personalized Therapies for Prostate Cancer. Sci. Transl. Med. 3, 72ps7 (2011).

View Full Text

Stay Connected to Science Translational Medicine